<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603834</url>
  </required_header>
  <id_info>
    <org_study_id>HE611336</org_study_id>
    <nct_id>NCT03603834</nct_id>
  </id_info>
  <brief_title>Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma</brief_title>
  <official_title>Prospective Phase II Study of Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous reports suggest benefit of neoadjuvant chemotherapy/chemoradiation treatment for
      borderline resectable cholangiocarcinoma. This study is a single center prospective phase II
      study of neoadjuvant chemotherapy with mFOLFOXIRI in patients with borderline resectable
      cholangiocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous reports suggest benefit of neoadjuvant chemotherapy/chemoradiation treatment for
      borderline resectable cholangiocarcinoma.

      This study is a single center prospective phase II study of neoadjuvant chemotherapy with
      mFOLFOXIRI in patients with borderline resectable cholangiocarcinoma.

      This phase 2 trial was designed to enroll 25 patients with BRCC who were assigned to
      mFOLFOXIRI neoadjuvant chemotherapy. The primary endpoint was the overall response rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of overall response evaluated by MRI or CT</measure>
    <time_frame>Up to 15 weeks</time_frame>
    <description>The rate of response evaluated by MRI or CT according to RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resectability rate</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The rate of patients who can successfully undergo surgery after chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>every 15 days for approximately 24 weeks</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>mFOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mFOLFOXIRI consists of the following combination of drugs:
Oxaliplatin, 85 mg/m2, IV over 2 hours Leucovorin, 400 mg/m2, IV over 2 hours Irinotecan, 150 mg/m2, IV over 90 minutes 5 FU, 400 mg/m2, IV bolus 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection
each 14 day cycle, for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOXIRI</intervention_name>
    <description>mFOLFOXIRI consists of the following combination of drugs:
Oxaliplatin, 85 mg/m2, IV over 2 hours
Leucovorin, 400 mg/m2, IV over 2 hours
Irinotecan, 150 mg/m2, IV over 90 minutes
5 FU, 400 mg/m2, IV bolus
5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection
each 14 day cycle, for 6 cycles</description>
    <arm_group_label>mFOLFOXIRI</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>Irinotecan</other_name>
    <other_name>Fluorouracil</other_name>
    <other_name>Leucovorin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years old at the time of informed consent

          2. Diagnosed with cholangiocarcinoma and the disease is measurable by RECIST 1.1 criteria

          3. ECOG performance status of 0 or 1

          4. No distant metastasis

          5. The disease is either resectable or potentially resectable

          6. Patients must have adequate organ function as defined by the following laboratory
             values at study entry:

             Hemoglobin ≥ 8 g/dL (transfusions are acceptable) ANC ≥ 1.5 x 109/L Platelets ≥ 100 x
             109/L AST/ALT ≤ 3 x ULN Total bilirubin ≤ 2.5 mg/dL Creatinine clearance ≥ 50 mL/min
             (estimated by Cockcroft-Gault or measured)

          7. Women of childbearing potential definition (WOCBP) and men must agree to use adequate
             contraception prior, to study entry, for the duration of study participation, and 3
             months after the end of treatment.

          8. WOCBP must have a negative serum or urine pregnancy test prior to initiation of
             treatment.

        Exclusion Criteria:

          1. &gt; 75 years old

          2. Prior therapy for cholangiocarcinoma with either surgery, radiation or chemotherapy

          3. Other malignancies except for the following: adequately treated cervical carcinoma in
             situ and treated basal cell carcinoma.

          4. Hypersensitivity to 5FU, oxaliplatin (or other platinum agents), irinotecan (or to
             their excipients).

          5. Pregnant or lactating women.

          6. Psychological, familial, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule; those conditions should be
             discussed with the patient before registration in the trial.

          7. Liver disease including but not limited to cirrhosis, primary sclerosing cholangitis,
             future liver remnant of less than 20-30%

          8. Comorbidity including but not limited to active clinically serious infections,
             congestive heart failure, life-threatening arrhythmia

          9. known HIV positive

         10. Baseline peripheral neuropathy/paresthesia grade ≥ 2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jarin Chindaprasirt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Khon Kaen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jarin Chindaprasirt, MD</last_name>
    <phone>6643366562</phone>
    <email>jarich@kku.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jaruda Sringam, Master</last_name>
    <phone>6643366562</phone>
    <email>talnurse8@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jarin Chindaprasirt</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jureerat Ratanaphet, Master</last_name>
      <phone>6643366592</phone>
      <email>jurepr@kku.ac.th</email>
    </contact>
    <investigator>
      <last_name>Jarin Chindaprasirt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aumkhae Sookprasert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kosin Wirasorn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Attapol Titapun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kulyada Somsap, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Watcharin Loilome, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Narong Kuntikheo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 17, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>October 8, 2019</last_update_submitted>
  <last_update_submitted_qc>October 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Jarin Chindaprasirt</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant</keyword>
  <keyword>Potentially resectable</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Bile duct cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

